Amgen Inc on Thursday reported a fourth-quarter profit well below Wall Street estimates, hurt by a steep decline in sales of blockbuster rheumatoid arthritis drug Enbrel and higher-than-expected expenses, and its shares fell nearly 2 percent. …
On Sunday, the world's largest independent biotechnology company, Amgen Inc. (Nasdaq: AMGN), bought Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) in a $10.4 billion dollar deal – making it the fifth-largest biotech deal in history …
"But giving the way the stock is reacting, maybe we're coming close to finding a bottom here." In the technology sector, Brady said Nokia has good fundamentals, so he's inclined to hold onto Nokia. He also said Amgen is a terrific company …
Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $180.12 to a high of $183.40. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $181.25 on volume of 792,000 …
By Mr. Loeb’s reckoning, a breakup could yield significant results. Given its current corporate self-help plan, Amgen appears set to improve its stock’s valuation to $189 a share by the end of 2016. But if the company splits itself in two, …
Novartis has obtained the marketing rights for Luxterna oustide the United States thereby building upon its gene therapy treatments which includes Kymriah.